Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia
Status:
Terminated
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This is a single center, single-blind randomized cross over design trial that will compare
the impact of intra-nasal naloxone vs. intra-nasal saline administration during experimental
hypoglycemia on day one on responses to experimental hypoglycemia on day two. Investigators
intend to enroll 18 individuals to obtain the complete data sets from 15 participants.
Expected duration of subject participation is 10-12 weeks. This study will consist of two
2-day intervention visits separated by approximately 8 weeks.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute